Aldeyra reports positive data from dry eye disease therapy trial

Aldeyra Therapeutics has reported positive top-line data from a 12-month safety clinical trial of reproxalap in dry eye disease patients.

In the multicentre, vehicle-controlled, parallel-group trial, 299 participants received treatment with reproxalap and 148 participants were treated with vehicle.